Diffuse large B‐cell lymphoma with phenotype switch, anaplastic features and aberrant T‐cell marker expression during disease evolution

Xiaoqiong Wang, Pei Lin, Jie Xu, Shaoying LieJHaem 2022 · DOI

TL;DR

This paper presents a striking case of Diffuse Large B-cell Lymphoma (DLBCL) that dramatically changed its characteristics upon relapse. The lymphoma switched from a non-germinal center B-cell (non-GCB) to a germinal center B-cell (GCB) phenotype, developed anaplastic features, and aberrantly expressed T-cell markers (CD3 and CD5). This highlights the remarkable plasticity of DLBCL and the potential for acquired genetic/epigenetic changes to drive therapeutic resistance and disease progression.

What Problem Does This Paper Address?

Diffuse Large B-cell Lymphoma (DLBCL) is a heterogeneous group of aggressive B-cell malignancies. While initial diagnoses and treatment responses can be predictable, understanding how DLBCL evolves over time, especially under the selective pressure of therapy, is crucial for improving patient outcomes. This paper addresses the challenge of characterizing and understanding the biological mechanisms behind DLBCL relapse, particularly when the lymphoma exhibits significant phenotypic and morphological shifts. The authors highlight the need to recognize these dynamic changes, as they can indicate therapeutic failure and guide more effective clinical management strategies.

Methods

The study employed standard histopathological and immunophenotypic techniques to analyze tissue biopsies from a single patient at two different time points: initial diagnosis and relapse.

  • Histopathology: Hematoxylin and eosin (H&E) staining was used to examine the morphology of the lymphoma cells.
  • Immunohistochemistry (IHC): This technique was used to detect specific protein markers on the lymphoma cells, helping to determine their lineage and subtype. Key markers included CD20, BCL-6, MUM1, MYC, BCL2, CD3, CD5, CD10, PAX5, TdT, and CD61. The proliferation index was assessed using Ki-67 staining.
  • Flow Cytometry: This method was used to analyze the surface markers of lymphoma cells in suspension, providing a detailed immunophenotypic profile.
  • Fluorescence In Situ Hybridization (FISH): This technique was used to detect specific chromosomal abnormalities, in this case, looking for MYC rearrangement.

The novelty lies not in the techniques themselves, which are standard in hematopathology, but in their application to track significant biological evolution within a single patient's disease.

Datasets

This paper describes a case study of a single patient. Therefore, there are no large datasets used for training or evaluation. The "dataset" consists of the initial and relapsed biopsies from this one individual.

Key Insights and Ideas

  • Remarkable Phenotypic Plasticity: DLBCL can undergo dramatic shifts in its immunophenotype, transitioning from a non-GCB to a GCB subtype. This challenges the notion of DLBCL as a static disease.
  • Acquired Anaplastic Features: The lymphoma developed anaplastic features, including pleomorphic and blastoid cells, some mimicking megakaryocytes. This morphological change is significant and can impact diagnostic classification.
  • Aberrant T-cell Marker Expression: The acquisition of CD3 and CD5 expression by B-cells is a critical finding. This "T-cell marker expression" in B-cell lymphoma is unusual and may contribute to therapeutic resistance or diagnostic confusion.
  • Therapeutic Resistance Driver: The authors propose that genetic/epigenetic alterations acquired during disease evolution are likely drivers of these phenotypic changes, contributing to therapeutic resistance and disease progression.
  • Clinical Implications: Recognizing these dynamic changes is essential for guiding appropriate clinical management, as standard treatment approaches may be less effective against a relapsed lymphoma with altered characteristics.

Key Results

The study details the following changes observed between the initial and relapsed DLBCL:

  • Initial Biopsy (non-GCB DLBCL): Lymphoma cells were positive for CD20, BCL-6, MUM1, MYC, and BCL2, and negative for CD3, CD5, and CD10.
  • Relapsed Biopsy (GCB DLBCL with anaplastic features):
    • Morphology: Changed from immunoblastic to diffuse infiltrate of large pleomorphic and blastoid lymphoid cells, with giant cells mimicking megakaryocytes.
  • Immunophenotype: * Gained expression of CD10 (diffuse), CD3 (subset), and CD5 (subset).
  • Remained positive for CD79a, PAX5, BCL-6, MUM1, MYC, and BCL-2.
  • Flow cytometry showed aberrant large B-cells expressing CD5 (partial), CD10, CD20, CD22, and monotypic kappa surface light chain, while lacking CD19.
  • Proliferation Index: Increased significantly to 80% (Ki-67).
  • MYC Rearrangement: FISH analysis showed no MYC rearrangement in the relapsed specimen.
  • Clinical Outcome: The patient was refractory to treatment and expired within one month of the relapsed diagnosis.

Limitations and Future Work

  • Single Case Study: The primary limitation is that this is a case report of a single patient. The observed changes may not be representative of all DLBCL relapses.
  • Mechanism of Change: While the authors suggest genetic/epigenetic alterations drive the changes, the specific molecular mechanisms are not elucidated in this paper.
  • Future Work: The authors emphasize the need for further research to understand the genetic and epigenetic drivers of DLBCL evolution. They also highlight the importance of recognizing these phenotypic alterations in clinical practice to guide treatment decisions and improve patient outcomes. Future studies could focus on larger cohorts to identify common patterns of evolution and develop targeted therapies for relapsed, refractory DLBCL with these complex features.

Summary updated

Abstract

A 41-year-old man was referred to our institution for relapsed diffuse large B-cell lymphoma (DLBCL). He was diagnosed with DLBCL, non-germinal center B-cell (non-GCB) immunophenotype at an outside hospital and received R-EPOCH for 6 cycles and reached complete remission. He relapsed 3 months later and received RICE (Rituximab, Ifosfamide, Carboplatin and Etoposide) chemotherapy and autologous stem cell transplant for persistent disease, then further received DHAP, and anti-CD19-CAR T-cell therapy combined with ibrutinib. He now progressed with extensive lymphadenopathy and extranodal involvement. The initial diagnostic biopsy of the cervical lymph node was reviewed and showed a diffuse infiltrate of large lymphoid cells with immunoblastic morphology (Image A-B). The lymphoma cells were positive for CD20 (Image C), BCL-6, MUM1, MYC and BCL2, and were negative for CD3 (Image D), CD5 and CD10, diagnostic of DLBCL, non-GCB type. In contrast, the current biopsy of the abdominal lymph node showed a diffuse infiltrate of large pleomorphic and blastoid lymphoid cells, with some giant mononucleated or multinucleated cells mimicking megakaryocytes (Image E-F). The lymphoma cells were positive for CD79a (Image G), PAX5, CD10 (diffuse, Image H), BCL-6, MUM1, MYC, BCL-2, CD3 (subset, image I) and CD5 (subset), and negative for TdT and CD61, with a proliferation index of 80% (Image J). Flow cytometry showed aberrant large B-cells expressing CD5 (partial), CD10, CD20, CD22, and monotypic kappa surface light chain and lacking CD19 (Image K-L) (Figure 1). Fluorescence in situ hybridization analysis showed no MYC rearrangement. The patient was diagnosed as DLBCL, GCB immunophenotype, with anaplastic features and aberrant T-cell marker expression. He was refractory to treatment and expired within 1 month. This relapsed DLBCL demonstrated drastic changes in both morphology (from immunoblastic to anaplastic) and immunophenotype (from non-GCB to GCB), and gained expression of CD10, CD3 and CD5. Recent literature has shown that genetic/epigenetic alterations acquired during the disease evolution drive phenotypic alterations in B-cell lymphoma, and play a critical role in priming lymphoma cell plasticity and therapeutic resistance. The phenotypic alterations and anaplastic features in this relapsed DLBCL patient indicate therapeutic failure and disease progression, and should be recognized and emphasized to guide appropriate clinical management. No funding was required for this study. Informed consent was obtained from the patient (“front-door” consent). PERMISSION TO REPRODUCE MATERIAL FROM OTHER SOURCES. The authors declare that they have no conflict of interest. The data that support the findings of this study are available from the corresponding author upon reasonable request.
BibTeX
@inproceedings{wang2022diffuse,
  author = {Xiaoqiong Wang and Pei Lin and Jie Xu and Shaoying Li},
  title = {{Diffuse large B‐cell lymphoma with phenotype switch, anaplastic features and aberrant T‐cell marker expression during disease evolution}},
  booktitle = {eJHaem},
  year = {2022},
  doi = {10.1002/jha2.546},
}
Figure